Company: Codagenix Inc.
Job title: Executive Vice President, Oncology
Workshop B – Regulatory Guidance for Clinical Stage Oncolytic Virotherapy 1:00 pm
As T-Vec exists as the only approved oncolytic virotherapy for patients, the regulatory environment and the clinical production of OV’s remain complex as ever. Led by biopharma leaders, this session will set out to deconvolute the regulatory landscape of OV clinical development, taking vital learnings from the Cell and Gene Therapy environment. Topics to Cover:…Read more
day: Pre-Conference Workshop Day
The Codon-Modified Virotherapeutic Codalytic™ Modulates The Tumor Microenvironment In Models With Different Immune Contextures 4:45 pm
Overview of Codagenix’s codon-modification platform and the design of CodaLytic Changes in the tumor microenvironment induced by CodaLytic, alone or in combination with checkpoint inhibitors, in murine models and a human tumor explant system Connection to efficacy outcomes, incl. tumor growth, survival and cytotoxicityRead more
day: Day One